greeksoup/ stock research
Stock research / United States / BCRX / Filings

Biocryst Pharmaceuticals Inc. SEC filings

Biocryst Pharmaceuticals filed 24 documents with the SEC in the last twelve months, the latest report being the 10-Q of 5 August 2026.

Filings in twelve months2415 of them 8-K news
Latest report10-Qfiled 5 Aug 2026
Latest filing10-Q5 Aug 2026
Last results, two-day move+3.1%results filed 5 Aug 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were other company news (10). Results came out 5 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 5 releases the share price moved 7.4% on average in the two days around results, the most on 26 Feb 2026 (+15.9%).

12 Jan 2026-8.8%$7.40 to $6.75
26 Feb 2026+15.9%$7.55 to $8.75
6 May 2026-1.4%$9.03 to $8.90
5 Aug 2026+3.1%$9.02 to $9.30
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

15 filings

Biocryst Pharmaceuticals's 15 news filings (8-K) were mostly about regulation FD disclosure (9) and results of operations (5).

  • Regulation FD disclosureMaterial shared with investors, often slides or a presentation
    9 · latest 5 Aug 2026
  • Results of operationsThe quarterly results release
    5 · latest 5 Aug 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    3 · latest 12 Jun 2026
  • Other eventsNews the company chose to file
    3 · latest 12 Jan 2026
  • Exit or disposal costsCosts to close or sell part of the business
    2 · latest 4 Aug 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 12 Jun 2026
  • Material agreementA large contract or deal was signed
    1 · latest 23 Jan 2026
  • Acquisition or disposition completedA purchase or sale of a business closed
    1 · latest 23 Jan 2026
  • New financial obligationNew debt or a borrowing
    1 · latest 23 Jan 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Biocryst Pharmaceuticals Inc. filed 24 documents with the SEC of the kinds listed here: 15 current reports (8-K), about 9 regulation FD disclosure; 5 results of operations; 3 officer or director change; 3 other events; 2 exit or disposal costs; 3 quarterly reports (10-Q), 1 employee share plan registration (S-8), 1 proxy statement (DEF 14A), 1 annual report to shareholders (ARS), 1 additional proxy material (DEFA14A), 1 annual report (10-K). The latest, filed 5 August 2026: 10-Q, quarterly report. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    5 August 202610-Qquarterly report30 June 2026EDGAR
    5 August 2026S-8employee share plan registrationEDGAR
    5 August 20268-KResults of operations, Regulation FD disclosure5 August 2026EDGAR
    4 August 20268-K/AExit or disposal costs25 June 2026EDGAR
    29 June 20268-KExit or disposal costs, Regulation FD disclosure25 June 2026EDGAR
    12 June 20268-KOfficer or director change, Shareholder vote11 June 2026EDGAR
    6 May 202610-Qquarterly report31 March 2026EDGAR
    6 May 20268-KResults of operations, Regulation FD disclosure6 May 2026EDGAR
    4 May 20268-KRegulation FD disclosure4 May 2026EDGAR
    23 April 2026DEF 14Aproxy statement11 June 2026EDGAR
    23 April 2026ARSannual report to shareholders31 December 2025EDGAR
    23 April 2026DEFA14Aadditional proxy materialEDGAR
    26 February 202610-Kannual report31 December 2025EDGAR
    26 February 20268-KResults of operations, Regulation FD disclosure26 February 2026EDGAR
    23 January 20268-K/AOfficer or director change14 October 2025EDGAR
    23 January 20268-KMaterial agreement, Acquisition or disposition completed, New financial obligation, Regulation FD disclosure23 January 2026EDGAR
    12 January 20268-KResults of operations, Regulation FD disclosure, Other events12 January 2026EDGAR
    9 January 20268-KRegulation FD disclosure9 January 2026EDGAR
    12 December 20258-KOther events12 December 2025EDGAR
    11 December 20258-KOfficer or director change9 December 2025EDGAR
    3 December 20258-KOther events3 December 2025EDGAR
    20 November 2025S-4merger registrationEDGAR
    4 November 202510-Qquarterly report30 September 2025EDGAR
    3 November 20258-KResults of operations, Regulation FD disclosure3 November 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.